Newsroom

You are here

For the media

Contact David Martinson at 651-624-7403 or dpmartin@umn.edu for media interviews with any expert within the University's health sciences programs. For academic or care-related requests, please contact the expert directly or through their clinic.

Media seeking experts outside the health sciences can reach the University's news service at 612-624-5551.

Biology of Osteosarcoma (BOOST) Registry and Biobank launches online for families, researchers battling osteosarcoma

Thursday, January 12, 2017

University of Minnesota researchers launch a new website commemorating Zach Sobiech and his legacy. The project brings patients with osteosarcoma together in one online location.  Found at osteosarcoma.umn.edu, the site is known as Biology of Osteosarcoma (BOOST) Registry and Biobank. The power of the project comes from the ability to bring people with a rare condition from anywhere in the world together to help better understand this disease.

UMN researchers provide molecular portraits of a new cancer drug target

Monday, December 19, 2016

Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.

 The research is published online in Nature Structural and Molecular Biology.

Frequent genetic changes in receptor related to prostate cancer care could cause treatment resistance

Wednesday, November 30, 2016

Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.

The paper is published in the latest issue of Nature Communications.

“We knew genetic rearrangements in the androgen receptor occurred in laboratory models of prostate cancer progression, and this could promote therapeutic resistance,” said Scott Dehm, Ph.D., associate professor in the Department of Laboratory Medicine and Pathology in the University of Minnesota Medical School and a member of the Masonic Cancer Center, University of Minnesota. “An outstanding question was if this reflected a mechanism of therapeutic resistance in prostate cancer patients, or whether it was unique to laboratory models.”